U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO (NIVOLUMAB) IN PREVIOUSLY TREATED PATIENTS WITH SMALL CELL LUNG CANCER AND GRANTS PRIORITY REVIEW